Blood test may predict cure and detect resistance in B-Cell cancers

NCT ID NCT03280394

Recruiting now Diagnosis Sponsor: Oncology Institute of Southern Switzerland Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study is testing whether a blood test that looks for tumor DNA in the bloodstream (called a liquid biopsy) can help doctors manage patients with mature B-cell tumors. The goal is to see if the test can accurately predict who is cured after treatment and identify early signs of drug resistance. Researchers will follow about 444 adults with various B-cell cancers, including Hodgkin lymphoma and diffuse large B-cell lymphoma, to compare the blood test results with standard outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Liquid Biopsy (blood test for cell-free DNA)
What this could lead to: If successful, this blood test could help doctors predict which patients are cured after treatment and spot early signs of drug resistance, guiding more personalized care.
What could go wrong: This is an observational study, not a treatment trial. The test may not prove accurate enough for routine use, and results may not apply to all types of B-cell tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates